Tuesday, March 31, 2020 11:23:03 PM
4:15 pm ET March 31, 2020 (Globe Newswire) Print
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the enrollment of the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, the company´s monoclonal anti-C5a antibody, in patients with severe COVID-19-induced pneumonia. The company has received initial positive human data from two initial patients suffering from COVID-19-induced severe pneumonia who were treated with BDB-001, an anti-C5a antibody produced by BDB from the IFX-1 cell line, in China. Data from the two patients are part of a larger investigation on the role of complement activation in COVID-19 which have been made publicly available through a pre-print server and have not been independently validated by InflaRx.
Based on the company´s existing pre-clinical research on the role of C5a in viral-induced pneumonia and the initial results from the BDB study, InflaRx has decided to initiate a clinical development program with IFX-1 in COVID-19 patients with severely progressed pneumonia. The company has received regulatory approval to start the trial in the Netherlands and enrolled the first patient at the Amsterdam University Medical Centers. Subject to regulatory approval, the company plans to initiate additional centers in Germany and potentially other European countries.
With regard to InflaRx's other ongoing clinical trials, the company is monitoring the impact of COVID-19 on its programs. The company's current clinical trial sites remain active; however, it is possible that sites have paused or will pause screening of new patients, and there may be other delays or consequences as the pandemic evolves. Therefore, we cannot predict the future impact on the programs or the company as a whole at present.
About IFX-1:
IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key "amplifier" of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis and Pyoderma Gangraenosum.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit www.inflarx.com.
On December 28, 2015, InflaRx entered into a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd., or BDB, for the use of the IFX-1 technology and cell line in BDB's development of drug candidates for sale in China. Pursuant to the agreement, InflaRx granted BDB an exclusive, non-transferable license to use the IFX-1 cell line and related intellectual property solely to develop and commercialize BDB's drug candidates, including BDB-001, in China. Pursuant to the agreement, InflaRx is entitled to receive royalties on net sales of BDB's products containing BDB-001 and reserves the right to commercialize products containing BDB-001 outside of China.
Contacts:
InflaRx N.V.
Jordan Zwick - Global Head of Business Development & Corporate Strategy
Email: jordan.zwick[at]inflarx.de
Tel: +1 917-338-6523
MC Services AG
New York Yankees and Duke Basketball
Recent IFRX News
- InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- InflaRx Announces Participation in September Investor Events • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/08/2024 11:35:23 AM
- InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 11:30:00 AM
- InflaRx to Report Second Quarter 2024 Results on August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) • GlobeNewswire Inc. • 06/24/2024 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 09:07:57 PM
- InflaRx Hosts R&D Event Highlighting the Promise of INF904 • GlobeNewswire Inc. • 06/05/2024 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2024 08:15:22 PM
- InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators • GlobeNewswire Inc. • 05/21/2024 06:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 12:43:48 PM
- InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event • GlobeNewswire Inc. • 04/24/2024 11:30:00 AM
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 11:30:00 AM
- InflaRx Appoints Jan Medina as Head of Investor Relations • GlobeNewswire Inc. • 02/22/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 01:00:15 PM
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients • GlobeNewswire Inc. • 01/25/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/04/2024 09:16:17 PM
- InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 • GlobeNewswire Inc. • 01/04/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 01:00:09 PM
- InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum • GlobeNewswire Inc. • 11/06/2023 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 12:04:10 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM